April 25, 2017

Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting

Apr 25, 2017  Wilson Therapeutics AB (publ), announced today a poster presentation at the 69th American Academy of Neurology (AAN) Annual Meeting in Boston, MA, 22-28 April, 2017...
Read more
April 25, 2017

Targovax ASA: First quarter 2017 results

Oslo, Norway, 25 April 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors...
Read more
April 24, 2017

Aarhus University Hospital in Denmark Purchases NBS System from Nexstim Plc

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for b...
Read more
April 24, 2017

Wilson Therapeutics presented positive final Phase 2 data for WTX101 at EASL Annual Meeting

Wilson Therapeutics AB (publ), announced today that the final data from the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class ...
Read more
April 24, 2017

Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)

Paris, April 24, 2017 – 18:30 CEST. Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) division and Onxeo S.A (Euronext Paris, Nasdaq ...
Read more
April 24, 2017

Capio acquires a Swedish eye specialist clinic in Stockholm

Capio has signed an agreement to acquire 100% of the shares in Globen Ögonklinik (PanSyn Sweden AB, including subsidiaries) (“Globen”). The clinic is specialized in ophthalmol...
Read more
April 20, 2017

Onxeo receives the EnterNext Tech 40 Label

Onxeo receives the EnterNext Tech 40 Label Onxeo is admitted to the “Tech 40” index, which incorporates 40 outstanding small and midcap Tech companies listed on the va...
Read more
April 20, 2017

Cash position and update on clinical developments for Q1 2017

Toulouse, FRANCE, Ann Arbor, UNITED-STATES, April 20, 2017, 6:30pm – Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical compan...
Read more
April 20, 2017

GenSight Biologics to Present GS010 at the 2017 Annual Meeting of the American Association of Neurology

Paris, France, April 20, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innova...
Read more
April 20, 2017

Targovax initiates first clinical trial with TG02, the second product from its RAS-peptide immunotherapy platform

First patient enrolled in a Phase Ib trial in patients with locally recurrent RAS-mutated rectal cancer Oslo, 20 April 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRV...
Read more